A Potential Immune Therapy for Mesothelioma

Cancer Discovery 2015 May 8 [Epub ahead of print] [Link]


Results from the KEYNOTE-028 trial show that pembrolizumab is well tolerated and improves clinical outcomes for patients with malignant pleural mesothelioma. Compared with second-line chemotherapy, the response rate achieved with this immune checkpoint inhibitor is considerably higher.